Stenocare AS (STENO) - Total Assets
Based on the latest financial reports, Stenocare AS (STENO) holds total assets worth Dkr11.87 Million DKK (≈ $1.86 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore STENO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Stenocare AS - Total Assets Trend (2018–2025)
This chart illustrates how Stenocare AS's total assets have evolved over time, based on quarterly financial data. See Stenocare AS net assets for net asset value and shareholders' equity analysis.
Stenocare AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Stenocare AS's total assets of Dkr11.87 Million consist of 37.3% current assets and 62.7% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 6.2% |
| Accounts Receivable | Dkr3.00 Million | 23.7% |
| Inventory | Dkr307.00K | 2.4% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr7.58 Million | 60.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Stenocare AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Stenocare AS market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Stenocare AS's current assets represent 37.3% of total assets in 2025, a decrease from 99.9% in 2018.
- Cash Position: Cash and equivalents constituted 6.2% of total assets in 2025, down from 83.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 60.0% of total assets.
Stenocare AS Competitors by Total Assets
Key competitors of Stenocare AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Stenocare AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.74 | 6.23 |
| Quick Ratio | 1.18 | 1.62 | 6.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr1.79 Million | Dkr3.94 Million | Dkr17.74 Million |
Stenocare AS - Advanced Valuation Insights
This section examines the relationship between Stenocare AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.60 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -35.8% |
| Total Assets | Dkr12.64 Million |
| Market Capitalization | $6.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Stenocare AS's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Stenocare AS's assets decreased by 35.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Stenocare AS (2018–2025)
The table below shows the annual total assets of Stenocare AS from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr12.64 Million ≈ $1.98 Million |
-35.82% |
| 2024-12-31 | Dkr19.69 Million ≈ $3.08 Million |
-48.34% |
| 2023-12-31 | Dkr38.12 Million ≈ $5.96 Million |
-3.74% |
| 2022-12-31 | Dkr39.60 Million ≈ $6.20 Million |
-9.86% |
| 2021-12-31 | Dkr43.94 Million ≈ $6.87 Million |
-22.02% |
| 2020-12-31 | Dkr56.34 Million ≈ $8.81 Million |
+78.25% |
| 2019-12-31 | Dkr31.61 Million ≈ $4.95 Million |
+45.59% |
| 2018-12-31 | Dkr21.71 Million ≈ $3.40 Million |
-- |
About Stenocare AS
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD, as well as CBD100 oil products. The company was incorporated in 2017 and is based in Randers, Denmark.